Genentech today announced plans to invest approximately $750 million in a new device fill-finish manufacturing facility at its 75-acre campus in Hillsboro, Oregon.
The Hillsboro investment follows the recent topping out of Genentech’s new manufacturing facility in Holly Springs, North Carolina.
The investment is expected to create 250 manufacturing jobs and approximately 200 construction jobs in Oregon during site development, with commercial operations expected to begin in 2031.
The new facility will support the manufacturing of drug delivery devices, such as pre-filled syringes and autoinjectors. These devices play an increasingly important role in how medicines are delivered and can provide patients with more convenient ways to receive treatment outside of a hospital setting.
Designed for flexibility, the facility will be capable of both high- and low-volume device filling across a broad range of Genentech’s portfolio.
Established in 2006, the Hillsboro campus is a critical hub in Genentech’s U.S. manufacturing network, supporting production across a broad range of therapeutic areas, such as oncology, immunology, and neurology. The new facility will add device filling capability to Genentech’s manufacturing network, helping strengthen U.S. production and support a more complete and secure domestic supply chain. Hillsboro’s existing infrastructure, proven manufacturing capabilities, and skilled workforce make it an ideal location for the new facility, building on nearly two decades of partnership with state and local community stakeholders in the region.
Roche and Genentech’s current U.S. footprint includes 13 manufacturing sites, 15 research and development sites and approximately 25,000 employees across 24 locations in eight states.
